Expanded Access to Velmanase Alfa

checkorphan
Learn more about:
Alpha-mannosidosis
Related Clinical Trial
Expanded Access to Velmanase Alfa Lamazym Aftercare Study Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients Evaluation of Long-term Efficacy of Treatment With Lamazym Clinical Biomarkers in Alpha-mannosidosis A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis Biomarker for Mannosidosis Disease (BioMannosidosis) Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

Brief Title

Expanded Access to Velmanase Alfa

Brief Summary

      Individual patient expanded access requests may be considered for patients who have no other
      treatment options.

Detailed Description

      Expanded access may provide access for treatment prior to approval by the local regulatory
      agency.

Study Type

Expanded Access

Condition

Alpha-Mannosidosis

Intervention

Velmanase Alfa

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Eligibility Criteria

        Inclusion Criteria:

        -

        Exclusion Criteria:

        -

Gender

All

Ages

N/A - N/A

Contacts

, (888) 661-9260, [email protected]

Administrative Informations

NCT ID

NCT04959240

Organization ID

Velmanase alfa-EAP

Responsible Party

Sponsor

Study Sponsor

Chiesi Farmaceutici S.p.A.

Study Sponsor

, ,

Verification Date

July 2021